Free tool
FAERS Monitor: Lamisil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020980 or its brand name (Lamisil, Terbinafine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,279
Serious
835
65% of reports
Hospitalization
330
Death reported
50
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective96
- pruritus77
- rash75
- nausea68
- fatigue63
- pain62
- dyspnoea56
- ageusia50
- diarrhoea47
- headache47
- weight decreased46
- cough42
- dysgeusia42
- off label use42
- dizziness40
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 28 |
| 2008 | 26 |
| 2009 | 17 |
| 2010 | 26 |
| 2011 | 23 |
| 2012 | 38 |
| 2013 | 15 |
| 2014 | 16 |
| 2015 | 54 |
| 2016 | 25 |
| 2017 | 43 |
| 2018 | 56 |
| 2019 | 73 |
| 2020 | 63 |
| 2021 | 79 |
| 2022 | 148 |
| 2023 | 147 |
| 2024 | 162 |
| 2025 | 157 |
| 2026 | 83 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,880 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ageusiaSignal | 50 | 33.0 | 25.2 | 1,520 |
| dysgeusiaSignal | 42 | 9.3 | 6.9 | 304 |
| pruritusSignal | 77 | 3.3 | 2.7 | 123 |
| rashSignal | 75 | 2.8 | 2.3 | 89 |
| weight decreasedSignal | 46 | 2.7 | 2.0 | 49 |
| coughSignal | 42 | 2.5 | 1.8 | 36 |
| pain | 62 | 1.7 | 1.3 | 16 |
| dyspnoea | 56 | 1.6 | 1.3 | 13 |
| nausea | 68 | 1.4 | 1.1 | 8 |
| fatigue | 63 | 1.3 | 1.0 | 5 |
| dizziness | 40 | 1.3 | 1.0 | 3 |
| headache | 47 | 1.2 | 0.9 | 2 |
| drug ineffective | 96 | 1.2 | 1.0 | 3 |
| diarrhoea | 47 | 1.2 | 0.9 | 1 |
| off label use | 42 | 0.8 | 0.6 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.